法匹拉韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "法匹拉韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

11doi.org

2^nd place

23^rd place

10web.archive.org

1^st place

9nih.gov

4^th place

5^th place

2reuters.com

49^th place

81^st place

1nikkeibp.co.jp

1,415^th place

1,538^th place

1nikkei.com

211^th place

266^th place

1allafrica.com

1,467^th place

3,389^th place

1nytimes.com

7^th place

31^st place

1sciencemag.org

857^th place

506^th place

1nhk.or.jp

145^th place

131^st place

1xinhuanet.com

309^th place

19^th place

1theguardian.com

12^th place

60^th place

allafrica.com (Global: 1,467^th place; Chinese: 3,389^th place)

Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea. AllAfrica - All the Time. [28 December 2014]. （原始内容存档于2016-03-23）.

doi.org (Global: 2^nd place; Chinese: 23^rd place)

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research. June 2009, 82 (3): 95–102. PMID 19428599. doi:10.1016/j.antiviral.2009.02.198.
Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research. November 2013, 100 (2): 446–54. PMC 3880838 . PMID 24084488. doi:10.1016/j.antiviral.2013.09.015.
Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Neglected Tropical Diseases. April 2014, 8 (4): e2790. PMC 3983105 . PMID 24722586. doi:10.1371/journal.pntd.0002790.
Zika Virus: Where Is the Treatment?. Current Treatment Options in Infectious Diseases. 2016, 8 (3): 208–211. PMC 4969322 . PMID 27547128. doi:10.1007/s40506-016-0083-7.
Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. The Journal of Infectious Diseases. April 2016, 213 (8): 1253–61. PMC 4799667 . PMID 26655300. doi:10.1093/infdis/jiv586.
Human Rabies - Virginia, 2017. MMWR. Morbidity and Mortality Weekly Report. January 2019, 67 (5152): 1410–1414. PMC 6334827 . PMID 30605446. doi:10.15585/mmwr.mm675152a2 （美国英语）.
Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. The Journal of General Virology. August 2014, 95 (Pt 8): 1619–24. PMID 24795448. doi:10.1099/vir.0.067199-0.
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research. May 2014, 105: 17–21. PMID 24583123. doi:10.1016/j.antiviral.2014.02.014.
Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Research. April 2014, 104: 153–5. PMID 24462697. doi:10.1016/j.antiviral.2014.01.012.
Cohen J. Results from encouraging Ebola trial scrutinized. Science. 26 February 2015 [21 January 2016]. doi:10.1126/science.aaa7912. （原始内容存档于2020-02-19）.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020 Feb doi:10.1038/d41573-020-00016-0

nhk.or.jp (Global: 145^th place; Chinese: 131^st place)

www3.nhk.or.jp

[1] （页面存档备份，存于互联网档案馆）NHK World News ‘China: Avigan effective in tackling coronavirus’

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research. June 2009, 82 (3): 95–102. PMID 19428599. doi:10.1016/j.antiviral.2009.02.198.
Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research. November 2013, 100 (2): 446–54. PMC 3880838 . PMID 24084488. doi:10.1016/j.antiviral.2013.09.015.
Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Neglected Tropical Diseases. April 2014, 8 (4): e2790. PMC 3983105 . PMID 24722586. doi:10.1371/journal.pntd.0002790.
Zika Virus: Where Is the Treatment?. Current Treatment Options in Infectious Diseases. 2016, 8 (3): 208–211. PMC 4969322 . PMID 27547128. doi:10.1007/s40506-016-0083-7.
Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. The Journal of Infectious Diseases. April 2016, 213 (8): 1253–61. PMC 4799667 . PMID 26655300. doi:10.1093/infdis/jiv586.
Human Rabies - Virginia, 2017. MMWR. Morbidity and Mortality Weekly Report. January 2019, 67 (5152): 1410–1414. PMC 6334827 . PMID 30605446. doi:10.15585/mmwr.mm675152a2 （美国英语）.
Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. The Journal of General Virology. August 2014, 95 (Pt 8): 1619–24. PMID 24795448. doi:10.1099/vir.0.067199-0.
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research. May 2014, 105: 17–21. PMID 24583123. doi:10.1016/j.antiviral.2014.02.014.
Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Research. April 2014, 104: 153–5. PMID 24462697. doi:10.1016/j.antiviral.2014.01.012.

nikkei.com (Global: 211^th place; Chinese: 266^th place)

富士フイルム、インフル薬「アビガン」のライセンスを中国大手に（页面存档备份，存于互联网档案馆）日経新聞 2016年6月23日

nikkeibp.co.jp (Global: 1,415^th place; Chinese: 1,538^th place)

medical.nikkeibp.co.jp

エボラ出血熱で世界が注目する日本発のある薬剤. 日経メディカル. 2014-08-11 [2014-08-18]. （原始内容存档于2020-08-09）.

nytimes.com (Global: 7^th place; Chinese: 31^st place)

Fink S. Ebola Drug Aids Some in a Study in West Africa. The New York Times. 4 February 2015 [2020-03-18]. （原始内容存档于2020-03-18）.

reuters.com (Global: 49^th place; Chinese: 81^st place)

First French Ebola patient leaves hospital. Reuters. 4 October 2016 [2020-03-18]. （原始内容存档于2020-02-19）.
BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus （页面存档备份，存于互联网档案馆）. Reuters Healthcare, February 16, 2020.

sciencemag.org (Global: 857^th place; Chinese: 506^th place)

Cohen J. Results from encouraging Ebola trial scrutinized. Science. 26 February 2015 [21 January 2016]. doi:10.1126/science.aaa7912. （原始内容存档于2020-02-19）.

theguardian.com (Global: 12^th place; Chinese: 60^th place)

Japanese flu drug 'clearly effective' in treating coronavirus, says China. The Guardian. 2020-03-18 [2020-03-18]. （原始内容存档于2020-03-18）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

エボラ出血熱で世界が注目する日本発のある薬剤. 日経メディカル. 2014-08-11 [2014-08-18]. （原始内容存档于2020-08-09）.
富士フイルム、インフル薬「アビガン」のライセンスを中国大手に（页面存档备份，存于互联网档案馆）日経新聞 2016年6月23日
First French Ebola patient leaves hospital. Reuters. 4 October 2016 [2020-03-18]. （原始内容存档于2020-02-19）.
Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea. AllAfrica - All the Time. [28 December 2014]. （原始内容存档于2016-03-23）.
Fink S. Ebola Drug Aids Some in a Study in West Africa. The New York Times. 4 February 2015 [2020-03-18]. （原始内容存档于2020-03-18）.
Cohen J. Results from encouraging Ebola trial scrutinized. Science. 26 February 2015 [21 January 2016]. doi:10.1126/science.aaa7912. （原始内容存档于2020-02-19）.
BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus （页面存档备份，存于互联网档案馆）. Reuters Healthcare, February 16, 2020.
[1] （页面存档备份，存于互联网档案馆）NHK World News ‘China: Avigan effective in tackling coronavirus’
Huaxia. Favipiravir shows good clinical efficacy in treating COVID-19: official. Xinhuanet.com, 17 March 2020. [2020-03-18]. （原始内容存档于2020-03-18）.
Japanese flu drug 'clearly effective' in treating coronavirus, says China. The Guardian. 2020-03-18 [2020-03-18]. （原始内容存档于2020-03-18）.

xinhuanet.com (Global: 309^th place; Chinese: 19^th place)

Huaxia. Favipiravir shows good clinical efficacy in treating COVID-19: official. Xinhuanet.com, 17 March 2020. [2020-03-18]. （原始内容存档于2020-03-18）.

法匹拉韦 (Chinese Wikipedia)

allafrica.com (Global: 1,467th place; Chinese: 3,389th place)

doi.org (Global: 2nd place; Chinese: 23rd place)

nhk.or.jp (Global: 145th place; Chinese: 131st place)

www3.nhk.or.jp

nih.gov (Global: 4th place; Chinese: 5th place)

ncbi.nlm.nih.gov

nikkei.com (Global: 211th place; Chinese: 266th place)

nikkeibp.co.jp (Global: 1,415th place; Chinese: 1,538th place)

medical.nikkeibp.co.jp

nytimes.com (Global: 7th place; Chinese: 31st place)

reuters.com (Global: 49th place; Chinese: 81st place)

sciencemag.org (Global: 857th place; Chinese: 506th place)

theguardian.com (Global: 12th place; Chinese: 60th place)

web.archive.org (Global: 1st place; Chinese: 1st place)

xinhuanet.com (Global: 309th place; Chinese: 19th place)